Medicare Part D Payments for Transmucosal Immediate-Release Fentanyl Drugs
Transmucosal Immediate-Release Fentanyl (TIRF) drugs are a Schedule II controlled substance. Medicare Part D covers TIRF drugs only for managing breakthrough pain in adult cancer patients who are already receiving and are tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain. We will determine whether TIRF drugs were appropriately dispensed in Medicare Part D in accordance with Medicare requirements.
|Announced or Revised||Agency||Title||Component||Report Number(s)||Expected Issue Date (FY)|
|Revised||Centers for Medicare and Medicaid Services||Medicare Part D Payments for Transmucosal Immediate-Release Fentanyl Drugs||Office of Audit Services||W-00-20-35846||2022|